Protein Kinases as Drug Targets

This book PDF is perfect for those who love Science genre, written by Bert Klebl and published by John Wiley & Sons which was released on 16 March 2011 with total hardcover pages 570. You could read this book directly on your devices with pdf, epub and kindle format, check detail and related Protein Kinases as Drug Targets books below.

Protein Kinases as Drug Targets
Protein Kinases as Drug Targets
Author : Bert Klebl
File Size : 46,5 Mb
Publisher : John Wiley & Sons
Language : English
Release Date : 16 March 2011
ISBN : 9783527633494
Pages : 570 pages
Get Book

Protein Kinases as Drug Targets by Bert Klebl Book PDF Summary

This timely guide to kinase inhibitor drug development is the first to cover the entire drug pipeline, from target identification to compound development and clinical application. Edited by the pioneers in the field, on the drug development side this ready reference discusses classical medicinal chemistry approaches as well as current chemical genomics strategies. On the clinical side, both current and future therapeutic application areas for kinase inhibitor drugs are addressed, with a strong focus on oncology drugs. Backed by recent clinical experience with first-generation drugs in the battle against various forms of cancer, this is crucial reading for medicinal, pharmaceutical and biochemists, molecular biologists, and oncologists, as well as those working in the pharmaceutical industry.

Protein Kinases as Drug Targets

Protein Kinases as Drug Targets by Bert Klebl,Gerhard Müller,Michael Hamacher

This timely guide to kinase inhibitor drug development is the first to cover the entire drug pipeline, from target identification to compound development and clinical application. Edited by the pioneers in the field, on the drug development side this ready reference discusses classical medicinal chemistry approaches as well as current

Get Book
Protein Kinases

Protein Kinases by Anonim

For the past two decades, the protein kinase family has been an intense area of research for developing anticancer drugs. Despite tremendous advancements in kinase drug expansion, many kinases are still unexplored. As such, this book includes research and review articles from experts that focus on protein kinase signalling pathways

Get Book
Protein Tyrosine Kinases

Protein Tyrosine Kinases by Doriano Fabbro,Frank McCormick

Leading researchers, from the Novartis group that pioneered Gleevec/GlivecTM and around the world, comprehensively survey the state of the art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights

Get Book
Kinase Drug Discovery

Kinase Drug Discovery by Richard A. Ward,Frederick Goldberg

Kinase drug discovery remains an area of significant interest across academia and in the pharmaceutical industry. There are now around 13 FDA approved small molecule drugs which target kinases and many more compounds in various stages of clinical development. Although there have been a number of reviews/publications on kinase research,

Get Book
Kinase Drug Discovery

Kinase Drug Discovery by Richard A. Ward,Frederick W. Goldberg

Kinase inhibition remains an area of significant interest, and growing importance, across academia and the pharmaceutical industry. There are now many marketed drugs that target kinases and a significant number of compounds are currently in various stages of clinical development. This book is a forward-looking analysis of a number of

Get Book
Protein Kinases in Drug Discovery

Protein Kinases in Drug Discovery by Rossen Donev

Protein Kinases in Drug Discovery, Volume 124 discusses the latest information on protein kinases and how they modify other proteins by chemically adding phosphate groups to them. New chapters in this release include Transport Proteins and AMPs: Implications in Human Disease, Protein kinase CK2 inhibition as a pharmacological strategy, Emerging role

Get Book
Tyrosine Kinases as Druggable Targets in Cancer

Tyrosine Kinases as Druggable Targets in Cancer by Huan Ren

Protein tyrosine kinase (PTK) deregulation contributes to growth of cancer and many other diseases. The development of small-molecule tyrosine kinase inhibitors (TKIs) that target the deregulated PTKs, such as epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) and Bcr-ABL in chronic myeloid leukemia (CML), has revolutionized disease management.

Get Book
Next Generation Kinase Inhibitors

Next Generation Kinase Inhibitors by Paul Shapiro

Protein kinases are fascinating enzymes that maintain the proper function of nearly every task performed by the cells of the human body. By extracting a phosphate from the energy molecule ATP and linking it to another protein, protein kinases alter the structure and ultimate function of other proteins. In this

Get Book